Abstract
Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.
Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.
Current Vascular Pharmacology
Title:Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Volume: 12 Issue: 1
Author(s): Ji-Yin Zhou, Lawrence Chan and Shi-Wen Zhou
Affiliation:
Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.
Abstract: Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.
Export Options
About this article
Cite this article as:
Zhou Ji-Yin, Chan Lawrence and Zhou Shi-Wen, Omentin: Linking Metabolic Syndrome and Cardiovascular Disease, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/1570161112999140217095038
DOI https://dx.doi.org/10.2174/1570161112999140217095038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy
Current Pharmaceutical Design Synthesis, Crystal Structure and Biological Evaluation of 4, 5, 6, 7-tetrahydropravastatin as HMG-CoA Reductase Inhibitor
Letters in Drug Design & Discovery Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry The Chemical Dynamics of NO and Reactive Nitrogen Oxides: A Practical Guide
Current Molecular Medicine Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective
Infectious Disorders - Drug Targets Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Current Neuropharmacology Current Hot Potatoes in Atrial Fibrillation Ablation
Current Cardiology Reviews The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins
Current Pharmaceutical Design Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Role of Intra-Luminal Pressure in Regulating PBF in the Fetus and After Birth
Current Pediatric Reviews The Burden of Pertussis in Patients with and without Recurrent Ischaemic Vascular Events
Infectious Disorders - Drug Targets Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Effects of Tai Chi Exercise on Physical and Psychological Health of Older People
Current Aging Science Mechanisms of Beta-Blockers Action in Patients with Heart Failure
Reviews on Recent Clinical Trials Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry